The role of azithromycin in patients with cystic fibrosis

Abdullah A Yousef; Adam Jaffe

doi:10.1016/j.prrv.2009.12.003

The role of azithromycin in patients with cystic fibrosis

Paediatr Respir Rev. 2010 Jun;11(2):108-14. doi: 10.1016/j.prrv.2009.12.003. Epub 2010 Jan 21.

Authors

Abdullah A Yousef¹, Adam Jaffe

Affiliation

¹ Department of Respiratory Medicine, Sydney Children's Hospital, High Street, Randwick 2031, University of New South Wales, Randwick, Sydney, Australia. Abdullah.Yousef@SESIAHS.HEALTH.NSW.GOV.AU

PMID: 20416547
DOI: 10.1016/j.prrv.2009.12.003

Abstract

Interest in azithromycin in the management of patients with cystic fibrosis has grown over the last decade. Uniquely this drug has both antibacterial and immune modulating effects which appear to be the reason for its clinical benefit as proven in several well designed clinical studies. In this review we discuss the proposed mechanisms of action of azithromycin and review the evidence for its clinical effectiveness and safety in cystic fibrosis.

Publication types

Review

MeSH terms

Anti-Bacterial Agents / administration & dosage
Anti-Bacterial Agents / adverse effects
Anti-Bacterial Agents / therapeutic use*
Azithromycin / administration & dosage
Azithromycin / adverse effects
Azithromycin / therapeutic use*
Cystic Fibrosis / drug therapy*
Cystic Fibrosis / immunology
Cystic Fibrosis / microbiology*
Cystic Fibrosis / physiopathology
Humans

Substances

Anti-Bacterial Agents
Azithromycin